- Published: 14 August 2014
- Written by Investor Ideas
Biotech News Alert: GenSpera (OTCQB:GNSZ) to Present at Rodman & Renshaw 16th Annual Global Investment Conference
CEO to Present Significance of Announced Clinical Trial Results for Lead Drug G-202 Treating Hepatocellular Carcinoma (HCC) Patientsto Wall Street Audience
SAN ANTONIO, Texas, August 14, 2014 – (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in New York.
The conference is attended by public companies, institutional investors, sophisticated private investors and industry executives.
GenSpera will be presenting at 12:05 pm Tuesday, September 9th. The Company will discuss the significance of the recently announced HCC clinical trial update for G-202, its lead drug candidate, as well as provide a corporate overview. The company has released interim results from the Phase Ib and ongoing Phase II study in hepatocellular carcinoma (HCC) patients who had previously progressed on, or who were intolerant of sorafenib (Nexavar®, a drug co-developed and co-marketed by Bayer and Onyx Pharmaceuticals, an Amgen subsidiary). Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study. In addition, imaging analysis demonstrated impressive blockade of tumor blood flow in the single patient evaluated by this method to date.
Hepatocellular carcinoma (HCC) is currently the sixth most common malignancy in the world and the third leading cause of cancer-related mortality worldwide.
Craig Dionne, PhD, GenSpera's CEO said of the pending conference,” I am excited to share the recent data and results for G-202 and its efficacy and safety analyses on patients to date. G-202 has potential to treat multiple cancers including prostate cancer and glioblastoma but our primary focus is currently hepatocellular carcinoma (HCC). The liver cancer data we recently presented at APPLE and other scientific conferences was overwhelmingly embraced by our peers; now this conference creates an opportunity to explain the significance and the promise it holds to the investment community.”
About the conference: http://www.rodm.com/
Read this release in full at http://www.investorideas.com/CO/GNSZ/news/2014/08141.asp
About GenSpera
GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera’s lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.
For more information, please visit the company’s website: www.genspera.com or follow us on Twitter @GenSperaNews.
Company presentations are available at: http://www.genspera.com/
Watch the Corporate Video:
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera’s periodic reports filed with the Securities and Exchange Commission.
CONTACT:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc. (210) 479-8112
Investors:
Steve Gersten
Capital Markets Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-813-926-8920
Media:
Dawn Van Zant
(800) 665 0411
Visit this company: www.genspera.com
More info on GNSZ at Investorideas.com Visit: http://www.investorideas.com/CO/GNSZ/
Disclaimer/Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18, 2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
